| Document |
Document Title |
|
WO/2021/229566A1 |
The present invention is directed to a composition including a Tryptophol derivative, a 4-Ethyl-Phenol derivative, or a combination thereof, and a method of using same, such as for treating a subject in need of modulation of blood coagul...
|
|
WO/2021/229501A1 |
The present invention relates to a composition comprising a combination or mixture of: (a) diosmin, (b) an extract of Betula pendula, (c) an extract of Hamamelis virginiana and (d) rutin useful in prevention and/or in the treatment of di...
|
|
WO/2021/229467A1 |
The invention relates to the field of medicine, specifically to hyperosmolar parenteral medicinal products in a dosage form of solutions for infusion. A combined hyperosmolar solution for infusion contains polyol, sodium chloride, potass...
|
|
WO/2021/229131A1 |
The present invention relates to coagulation factor V deficiency and gene editing (CRISPR) for the correction in vitro of mutations in the F5 gene and the generation of tools to cure this currently untreatable disease. The invention incl...
|
|
WO/2021/227405A1 |
An etamsylate injection and a preparation method therefor. The preparation steps are as follows: preparing saturated solutions of etamsylate, edetate disodium, sodium metabisulfite and sodium chloride for later use; dissolving mannitol, ...
|
|
WO/2021/228866A1 |
The invention relates to an anti-thrombotic molecule having both anti-platelet and anti-coagulant (APAC) activity and, in particular, its use as a medicament to prevent and/or treat heparin-induced thrombocytopenia (HIT) type I or II; an...
|
|
WO/2021/231470A1 |
Provided are methods for treating paroxysmal nocturnal hemoglobinuria in a subject who previously exhibited an inadequate response to an anti-C5 antibody therapy, by administering to the subject a therapeutically effective amount of an i...
|
|
WO/2021/228366A1 |
Uses and formulations of cannabinoids, in particular of cannabidiol, are provided. The cannabinoids, in particular cannabidiol, are used for the treatment of patients suffering from inflammatory conditions associated with autoimmune dise...
|
|
WO/2021/226677A1 |
The present disclosure relates to the use of anti-platelet agents for the treatment of thrombosis and related conditions in a subject. The anti-platelet agent, preferably a phosphoinositide 3-kinase beta (ΡΙ3Κβ) inhibitor such as TGX...
|
|
WO/2021/223480A1 |
Provided are a controlled-release ticagrelor tablet and a preparation method therefor, wherein the controlled-release tablet comprises a tablet core and a film-controlled coating system, the tablet core comprises ticagrelor accounting fo...
|
|
WO/2021/224354A1 |
The present invention relates to a pharmaceutical combination comprising (i) firibastat, (ii) a diuretic and (iii) a blocker of the systemic renin-angiotensin system selected from the group consisting of angiotensin I converting enzyme i...
|
|
WO/2021/223732A1 |
An acetic acid-free blood purification concentrate, which is a solid or liquid preparation, and an acid-base regulator contained in the blood purification concentrate is a mixture of citric acid and one, two or three of fumaric acid, mal...
|
|
WO/2021/224146A1 |
The present invention provides methods of alleviating hypoxemia in a subject through oral administration of a methylthioninium compound.
|
|
WO/2021/222353A1 |
The present disclosure relates to novel compounds for use in therapeutic treatement of a disease associated with peptidylarginine deiminases (PADs), such as peptidylarginine deiminase type 4 (PAD4). The present disclosure also relates to...
|
|
WO/2021/222875A1 |
The invention relates to methods of treating multiple osteochondroma and anemia resulting from iron imbalance using small molecule ALK2 inhibitors.
|
|
WO/2021/222549A1 |
The present invention relates to RNAi agents, e.g., dsRNA agents, targeting the complement fator B (CFB) gene. The invention also relates to methods of using such RNAi agents to inhibit expression of a CFB gene and to methods of treating...
|
|
WO/2021/222359A1 |
The subject matter described herein is directed to ferroportin inhibitor compounds of Formula I and pharmaceutical salts thereof, methods of preparing the compounds, pharmaceutical compositions comprising the compounds, and methods of ad...
|
|
WO/2021/217734A1 |
A compound or a pharmaceutically acceptable salt thereof or a stereoisomer or isotope labeled compound thereof. The compound has a good inhibition effect on ketohexokinase. Provided are a pharmaceutical composition containing the compoun...
|
|
WO/2021/222424A1 |
The present disclosure provides a method of treating a condition associated with aging, including a disease or condition selected from anemia, including unexplained anemia of the elderly, spontaneous anemia of aging, and anemia of inflam...
|
|
WO/2021/222363A1 |
The subject matter described herein is directed to ferroportin inhibitor compounds of Formula I or I' and pharmaceutical salts thereof, methods of preparing the compounds, pharmaceutical compositions comprising the compounds, and methods...
|
|
WO/2021/216944A1 |
Methods of increasing microvascular blood flow in the muscle of a human subject comprise orally administering about 100 to about 800 mg cocoa flavanols per day in a nutritional composition comprising at least one source of protein, to a ...
|
|
WO/2021/213504A1 |
The present invention provides use of a VEGF inhibitor in preparation of a medicament for treating hypoxia-related diseases. The VEGF inhibitor can significantly inhibit VEGF stress expression caused by hypoxia by acting on a binding pat...
|
|
WO/2021/214175A1 |
The present invention relates to the therapeutic use of alpha-2 adrenergic receptor agonists in the prevention and/or treatment of spleen disorders, in particular splenomegaly. The inventors showed that clonidine, guanabenz and romifidin...
|
|
WO/2021/208552A1 |
Disclosed is the use of thyroid hormone and an analogue thereof in preparation of drugs for treating alpha-thalassemia. The thyroid hormone and the analogue can be specifically used in regulating the expression of zeta-globin gene. In a ...
|
|
WO/2021/209459A1 |
Provided herein are solid dispersions comprising rifaximin and methods of using the same for the treatment of sickle cell disease (SCD).
|
|
WO/2021/211044A1 |
The invention relates to dextran sulfate, or a pharmaceutically acceptable salt thereof, in treatment of sepsis and hypercytokinemia.
|
|
WO/2021/210650A1 |
A compound indicated by formula (I) or a pharmacologically acceptable salt thereof is provided as a compound that can be a therapeutic or prophylactic drug for TRPC6-related diseases, such as nephrotic syndrome, membranous nephropathy, a...
|
|
WO/2021/209740A1 |
The invention relates to treatments for coronavirus infections by administering a neutrophil elastase inhibitor, such as alvelestat.
|
|
WO/2021/210667A1 |
The present invention provides a bispecific antigen-binding molecule that recognizes both of two specific factors out of various coagulation-related factors, as well as a composition and a kit containing the bispecific antigen-binding mo...
|
|
WO/2021/211890A1 |
In one aspect, the disclosure relates to pharmaceutical compositions comprising 2'-deoxycytidine analogs, oral and other dosage formulations containing the same, and methods of making the same. In another aspect, the disclosure relates t...
|
|
WO/2021/208551A1 |
An application of thyroid hormone and an analogue thereof in the preparation of a drug for treating sickle-cell disease. Specifically, thyroid hormone and the analogue thereof can be applied in the regulation of the expression of ζ-glob...
|
|
WO/2021/211745A1 |
Provided herein are methods and uses involving pirfenidone pharmaceutical compositions (e.g., extended-release pirfenidone pills (e.g., tablets)) in treating COVID-19, treating and/or preventing viremia and/or viremia-induced disease cau...
|
|
WO/2021/210925A1 |
The present invention relates to a novel compound which exhibits the effect of treating, preventing, or ameliorating lymphedema, and a composition comprising same as an active ingredient, the composition being applied as medicines, funct...
|
|
WO/2021/204705A1 |
The use of carboxylate ligand modified ferric iron hydroxide compositions for the treatment or prevention of iron deficiency associated with liver diseases is disclosed, and more particularly to the class of Iron Hydroxide Adipate Tartra...
|
|
WO/2021/207072A1 |
Antibodies and antigen-binding fragments thereof that bind type II transmembrane serine protease 6 (TMPRSS6) on the surface of a cell and increase hepcidin expression, and methods for treating disorders of iron metabolism using anti TMPR...
|
|
WO/2021/205401A1 |
The present disclosure relates to recombinant proteins comprising a feline granulocyte colony-stimulating factor and an antigen binding fragment that binds to serum albumin, nucleic acid molecules encoding the recombinant proteins, vecto...
|
|
WO/2021/207659A1 |
Disclosed are crystalline forms of Compound (I). Compound (I) is useful as an anti-thromboembolic agent in the treatment of cardiovascular diseases.
|
|
WO/2021/201813A1 |
The invention relates to the method of the inhibition of the fibrin polymerization by synthetic peptides mimicking fragments of the coiled-coil region fibrin(ogen), in which is used a mixture of non-immunogenic synthetic structural pepti...
|
|
WO/2021/200694A1 |
[Problem] To provide a novel compound that has read-through activity and is useful as an agent for preventing or treating nonsense-mutation genetic disorders. [Solution] One embodiment of the present invention provides a compound represe...
|
|
WO/2021/202031A1 |
Embodiments of the disclosure concern methods and compositions of treating or preventing viral infection, including of SARS-CoV-2, for example. In specific embodiments, one or more adjuvants are delivered to an individual receiving and/o...
|
|
WO/2021/202796A1 |
The subject matter described herein is directed to pyruvate kinase activating compounds of Formula I and pharmaceutical salts thereof, methods of preparing the compounds, pharmaceutical compositions comprising the compounds and methods o...
|
|
WO/2021/202735A1 |
The subject invention relates to novel methods for the treatment of viral or bacterial induced respiratory disease with hypoxemia.
|
|
WO/2021/197639A1 |
The present disclosure relates to methods of treating or preventing hematologic disorders by administration of 15-HEPE or compositions thereof.
|
|
WO/2021/197451A1 |
A multiple formulation for once-a-day administration of ticagrelor or a pharmaceutically acceptable salt thereof, said multiple formulation comprising an immediate-release multiple unit portion and a sustained-release multiple unit porti...
|
|
WO/2021/202948A2 |
Provided herein are methods for treating acute respiratory distress syndrome (ARDS), such as ARDS associated with respiratory virus infection, involving administering an inhibitor of the contact activation pathway. Also provided herein a...
|
|
WO/2021/202836A1 |
This invention relates to factor B inhibitors or nucleic acid molecules encoding thereof and selective inhibition of the alternative pathway (AP) of the complement system using said factor B inhibitors or nucleic acid molecules encoding ...
|
|
WO/2021/202284A1 |
The present disclosure relates generally to compounds and pharmaceutical compositions suitable as modulators of hemoglobin and methods for their use in treating disorders mediated by hemoglobin. (Formula (I))
|
|
WO/2021/203146A1 |
The present invention relates to preparation pain-relieving rooted from natural herbs for preventing and treating thrombosis, wherein the preparation comprises the blood activating component including at least three of group medicinal he...
|
|
WO/2021/202032A1 |
Embodiments of the disclosure encompass methods and compositions related to treatment of Acute Respiratory Distress Syndrome caused by any reason, including caused by a coronavirus, for example. In particular embodiments, fibroblasts are...
|
|
WO/2021/197283A1 |
The invention discloses a synthetic peptide amide compound, which belongs to the field of medicine, and specifically discloses a synthetic peptide amide compound containing a boronic acid group and a preparation method thereof. The inven...
|
